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FMD Vaccine Surge Capacity for Emergency Use in the United States
Abstract
Foot and mouth disease (FMD) presents the greatest economic threat to U.S. animal agriculture and is viewed
as the most important transboundary animal disease in the world. An outbreak of FMD in the U.S. would have
a devastating impact on the U.S. economy extending far beyond animal agriculture. The structure of modern
animal agriculture in the U.S., including extremely large herds and extensive intraand inter‐state movement of
animals and animal products will make it nearly impossible to control an FMD outbreak in livestock dense
areas without the rapid use of tens of millions of doses of FMD vaccine. The amount of antigen in the North
American FMD Vaccine Bank is far below what would be needed to provide vaccine for a single livestock
dense state. It would take many months to produce/obtain the volume of vaccine needed. Without sufficient
vaccine to aid in the response, FMD could rapidly spread across the U.S., resulting in the destruction and
disposal of potentially millions of animals, and become an endemic disease in livestock with spread potentially
facilitated by deer, feral swine or other freeliving animals. It would then require a much more extensive control
program and could take many years to eradicate. Agriculture is critical infrastructure in the U.S. and cash
receipts for livestock and poultry often exceed $100 billion per year. Therefore, it is urgent to develop a plan to
ensure that adequate supplies of FMD vaccine with multiple strains of FMD virus are rapidly available in the
event of an accidental or intentional introduction of FMD virus into the U.S. This white paper is part of an
effort by the private sector stakeholder community to work with the Secretaries of Agriculture and Homeland
Security as directed in Homeland Security Presidential Directive 9 to develop a National Veterinary Stockpile
(NVS) with sufficient quantities of FMD vaccine to protect U.S. agriculture, food systems, and the economy.
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Species  Population  Units  Establishments
Cattle  90,768,500  Animals  922,000
Sheep  5,345,000  Animals  80,000
Goats  2,862,000  Animals  151,000
Camelidae  122,680  Animals  26,060
Buffaloes  198,234  Animals  4,499
Swine  65,931,000  Animals  69,100




































































































































































































































































































































































7. VACCINES APPROVED FOR INCLUSION IN THE NVS AND FOR EMERGENCY 






















































9. IMPORTANCE OF EXPEDITED PROCESS FOR SWITCHING VACCINE 
























10. DESIRABLE CHARACTERISTICS OF VACCINES AND OF VACCINE 










































11. APPROACHES AND GOALS FOR ASSURING SURGE CAPACITY FOR FMD 











































































































13. SUMMARY OF POTENTIAL SOLUTIONS TO PROVIDE ADEQUATE FMD 
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Section I: Comparison of FMD Vaccines: Conventional 
Inactivated Vaccines, Leaderless LL3B3D Inactivated 
Vaccines, hAd5 Vectored Vaccines, Alphavirus Replicon 
Vaccines and Plasmid DNA Vaccines 
 

























Involved in cleavage of viral 
polypeptide; also cleaves host proteins 
to reduce translation of host mRNAs1;  
Not necessary for capsid assembly1-3 
Modified in leaderless FMD 
vaccine 
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2A Protease, involved in cleavage of 
FMDV polypeptide1; 
Not necessary for capsid assembly1-3 
Included in hAd5-vectored 
FMD vaccines  
2B Alteration in cell functions, including 
changes in endoplasmic reticulum and 
Golgi; involved in RNA amplification.1 
Proteins 2B, 2C, and 3A have been 
implicated in membrane rearrangements 
that produce the cytoplasmic vesicles 
where FMDV replicates.4  
Full length gene included in 
a recent version of the 
hAd5-vectored A24 Cruzeiro 
vaccine, resulted in 
improved efficacy 
2C May be involved in host cell membrane 
changes that eventually allow release of 
virions; directs replication complexes to 
cell membrane; may be involved in 
virus encapsidation.1 Proteins 2B, 2C, 
and 3A have been implicated in 
membrane rearrangements that produce 
the cytoplasmic vesicles where FMDV 
replicates.4  
 
3A Inhibits MHC class I expression; 
involved in changes in cell functions.1 
Changes in 3A might influence outcome 
of infection, result in changes in host 
range.1 Proteins 2B, 2C, and 3A have 
been implicated in membrane 
rearrangements that produce the 
cytoplasmic vesicles where FMDV 
replicates.4  
Most commercial NSP 
(ELISA) tests are based on 
the 3AB or 3ABC protein, 
and are used as serological 
DIVA tests with 
conventional inactivated 
vaccines and some 
experimental FMD 
vaccines.  
3B Involved in synthesis of FMDV RNA; 
stimulates 3CD autocleavage (as 3AB).1 
Modified to give DIVA 
capability in the leaderless 
LL3B3D FMD vaccine; 
Test based on this protein is 
in development as a 
serological DIVA test for 
hAd5-vectored vaccine. 
Most commercial NSP 
(ELISA) tests are based on 
the 3AB or 3ABC protein, 
and are used as serological 
DIVA tests with 
conventional inactivated 
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vaccines and some 
experimental FMD 
vaccines. The 3B protein is 
the target for the 
competitive monoclonal 
antibodies used in most 
commercial cELISA tests. 
3C Protease required for capsid assembly; 
involved in host protein synthesis 
shutoff and transcription inhibition; 
RNA binding in RNA replication.1,3 
Included in hAd5-vectored 
FMD vaccines to produce 
empty capsids from the P1-
2A precursor.5-7 cited in 8  
Most commercial NSP 
(ELISA) tests are based on 
the 3AB or 3ABC protein, 
and are used as serological 
DIVA tests with 
conventional inactivated 
vaccines and some 
experimental FMD 
vaccines. 
3D Viral RNA-dependent RNA polymerase 
(synthesis of FMDV RNA); produces 
both positive sense and negative sense 
RNA.1  
Often incorporated into the 
capsid and cannot be 
purified from conventional 
inactivated vaccines.1,9;  
Modified to give DIVA 












































































2.2 Differentiation of vaccinated from infected animals based on serological 





















































































































3.1 Desirable vaccine characteristics 
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3.1.1 Rapid onset of immunity 












































































































































































































































3.1.7 Knowledge of the level of herd immunity needed to stop transmission in a 



































































3.2 Desirable characteristics for vaccine manufacture and stockpiling 

























3.2.4 Capability of meeting requirements for cost effective manufacturing and all 





3.2.5 Desirable characteristics for stockpiling for emergency use 
3.2.5.1 Ongoing manufacture and sale in endemic countries which enables indefinite 







































































3.3 Desirable characteristics for vaccine administration 


































3.4 Desirable characteristics for minimizing the impact on food production 
and animal trade 
3.4.1 Safety for use in food producing animals with no, or reasonably short, withdrawal 
time for animal products for human consumption 

































































3.5 Desirable characteristics for controlling FMD in wild and feral 
populations 
























































4.1 Desirable vaccine characteristics 





























































4.1.7 Knowledge of the level of herd immunity needed to stop transmission in a 












4.2 Desirable characteristics for vaccine manufacture and stockpiling 

































































4.2.4 Capability of meeting requirements for cost effective manufacturing and all 








4.2.5 Desirable characteristics for stockpiling for emergency use 
4.2.5.1 Ongoing manufacture and sale in endemic countries which enables indefinite delivery/ 
























































4.3 Desirable characteristics for vaccine administration 













4.4. Desirable characteristics for minimizing the impact on food production 
and animal trade 
 
4.4.1 Safety for use in food producing animals with no, or reasonably short, withdrawal 
time for animal products for human consumption 



































4.5 Desirable characteristics for controlling FMD in wild and feral 
populations 























































5.1 Desirable vaccine characteristics 





























































































































5.2 Desirable characteristics for vaccine manufacture and stockpiling 






































5,2.4 Capability of meeting requirements for cost effective manufacturing and all 









5.2.5 Desirable characteristics for stockpiling for emergency use 
5.2.5.1 Ongoing manufacture and sale in endemic countries which enables indefinite 









5.2.5.2 Stability when stored as bulk antigen 
Human Ad5‐vectored FMD vaccines are made as ready‐to‐use products.2  
 















































5.3 Desirable characteristics for vaccine administration 





































5.4 Desirable characteristics for minimizing the impact on food production 
and animal trade 
5.4.1 Safety for use in food producing animals with no, or reasonably short, withdrawal 
time for animal products for human consumption 































































5.5 Desirable characteristics for controlling FMD in wild and feral 
populations 































































6.1 Desirable vaccine characteristics 




















































































6.2 Desirable characteristics for vaccine manufacture and stockpiling 

























6.2.4 Capability of meeting requirements for cost effective manufacturing and all 








6.2.5 Desirable characteristics for stockpiling for emergency use 
6.2.5.1 Ongoing manufacture and sale in endemic countries which enables indefinite 












































6.6 Desirable characteristics for vaccine administration 






































6.7 Desirable characteristics for minimizing the impact on food production 
and animal trade 














6.7.2 Safety for use in food producing animals with no, or reasonably short, withdrawal 
time for animal products for human consumption 
























































6.8 Desirable characteristics for controlling FMD in wild and feral 
populations 





7. PLASMID DNA VACCINES 













































































































7.1 Desirable vaccine characteristics 





























































7.2 Desirable characteristics for vaccine manufacture and stockpiling 




7.2.2 Vaccine organism is not a select agent 
Plasmids are not considered to be select agents. 
 













7.2.4 Capability of meeting requirements for cost effective manufacturing and all 











7.2.5 Desirable characteristics for stockpiling for emergency use 
7.2.5.1 Ongoing manufacture and sale in endemic countries which enables indefinite 

















































7.3 Desirable characteristics for vaccine administration 






























































7.4 Desirable characteristics for minimizing the impact on food production 
and animal trade 
7.4.1 Safety for use in food producing animals with no, or reasonably short, withdrawal 
time for animal products for human consumption 



































7.5 Desirable characteristics for controlling FMD in wild and feral 
populations 









Section II: Antiviral Prophylaxis for the Control of Foot 











































































































































































































































































































3. Nucleic acid strategies, including RNA interference 
Nucleic acid strategies have also been tested for their ability to suppress FMDV 
replication. Some methods that appear promising in cells and laboratory rodent models 
include the use of small interfering RNAs (siRNA),216,254‐259 micro RNA260 and in vitro 
transcribed RNAs that mimic structural domains in noncoding regions of FMDV and 
induce cytokines and innate immune responses.261 Currently, only the siRNA strategy 
has been tested in any livestock species.254,255 
Small interfering RNAs are short, double‐stranded RNA molecules that are homologous 
to part of the target gene, and cause their complementary mRNA in the cell to be 
degraded.216,254,255 This posttranscriptional gene silencing mechanism, called RNA 
interference, is thought to be an evolutionarily conserved mechanism in eukaryotes.255 
It may function in gene regulation and in helping to maintain the stability of the 
genome, and it is also thought to be a viral defense mechanism in plants and 
insects.254;262 cited in 255 Because of the rapidity and specificity of RNA interference, siRNA 
has been investigated as one method of inhibiting pathogen replication, either alone or 
combined with other agents. One impediment to using siRNA is that, for optimal 
efficacy, the vector used to express the RNA should have a similar distribution in tissues 
as FMDV.254,255 Other challenges include the short duration of the siRNA effect, and its 
inability to completely clear viruses.254 In addition, there are still uncertainties in how 
well this system would work in the field.216  
Two studies examined the siRNA system in FMDV‐infected livestock, and also in cells 
and laboratory rodents. In one experiment, hAd5‐vectors that expressed short‐hairpin 
RNAs against either the FMDV structural protein 1D (hAd5‐NT21) or the 3D polymerase 
(hAd5‐POL) were initially shown to suppress the replication of homologous FMDV in 
swine cells.254 The hAd5‐POL construct also inhibited the replication of heterologous 
FMDV in cells, and it was partially protective against homologous challenge, 1 day after 
administration, in a guinea pig model.254 The siRNA technique was then tested in swine. 
A mixture of hAd5‐NT21 and hAd5‐POL protected 2 of 3 pigs from clinical signs, and 
resulted in delayed and milder clinical signs in the third animal.254 A lower dose resulted 
in full clinical protection in one animal and partial protection in two pigs. Viremia also 
appeared to be decreased in treated pigs, although it was not systematically examined. 
  80
One difficulty identified in this experiment is that the hAD5‐vectored constructs do not 
seem to concentrate in the tissues where FMDV usually replicates.254 In guinea pigs, 
FMDV occurred mainly in the epithelial cells of clinically affected feet, but the vast 
majority of the hAd5 vector was found in the liver. An additional concern with the use of 
hAd5 vectors is that the VA1 noncoding region of adenoviruses can inhibit the 
biogenesis of siRNA and microRNA.263 cited in 254 
A later study employed a different vector, and also focused solely on RNA interference 
directed against conserved regions of the FMDV genome. This may be a safer strategy 
than targeting siRNA to structural proteins, as the latter agents may not be well 
matched to the virus in an emerging outbreak.264‐267 cited in 255 In this experiment, 
plasmids that expressed siRNA were generated against highly conserved sequences 
within the NSPs 3D and 2B.255 These plasmids decreased the replication of serotype O 
and Asia1 viruses in cells, and were promising in mice. An attenuated Salmonella 
choleraesuis (C500) vaccine strain that expressed the siRNA against 3D was then 
constructed. This vector was chosen because attenuated S. choleraesuis tends to 
localize to the lymph node, tonsil, lung and gastrointestinal tract of pigs.268 cited in 255 In a 
laboratory rodent model, S. choleraesuis‐vectored 3D siRNA protected 80% of guinea 
pigs challenged after 36 hours.255 Lastly, swine given 5 × 109 CFU of this construct and 
challenged one day later with serotype O FMDV (strain HKN/2002) had milder and 
delayed clinical signs compared to controls. Antibody titers to NSPs were also much 
lower, suggesting that virus replication was decreased. A higher dose of the construct 
was less effective, possibly because low doses of the Salmonella vector are better able 
to evade anti‐vector immune responses.255 
 
4. Summary 
Currently, hAd5‐vectored IFN is the only form of antiviral prophylaxis that has been 
evaluated extensively in livestock. While this technique is promising in swine, the need 
for high doses of these constructs could be a challenge for widespread use in large 
numbers of animals.238,247 Injection into multiple sites results in a tenfold reduction in 
the amount needed,238 but this method will also complicate administration in the field. 
In addition, the dose needed to suppress FMDV replication is still relatively high, and the 
technique thus remains costly.247 Co‐administration with other antivirals may allow 
additional dose reductions.22,247 The ability of hAd5‐vectored IFN to protect cattle from 
FMDV is still in question, as constructs expressing type I or type III interferons provided 
only partial protection in two studies.234,239 These agents have not been tested in small 
ruminants in the U.S., and there are no published reports of testing in other countries. 
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There is still limited information on other forms of prophylaxis. One antiviral drug, T‐
1105, appeared to be promising against FMDV challenge in pigs;221 however, these 
experiments have apparently not been formally published. In addition, this agent does 
not seem to have been tested yet in other livestock species. The interferon inducer poly 
ICLC also seemed to be effective in some animals, when used alone.247 RNA interference 
may provide some protection; however, siRNA has only been tested in pigs, which were 
partially protected in the two published experiments.254,255 Nevertheless, it is intriguing 
to note a recent report that hAd5‐vectored IFNα combined with hAd5‐vectored siRNA 
was synergistic in cultured cells and mice.22 Antiviral agents will need to be tested in 
each animal species that will be treated, as potential adverse effects, as well as 
effectiveness, may vary between species. 
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